GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » EV-to-EBITDA

StageZero Life Sciences (StageZero Life Sciences) EV-to-EBITDA : -0.41 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, StageZero Life Sciences's enterprise value is $4.93 Mil. StageZero Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.02 Mil. Therefore, StageZero Life Sciences's EV-to-EBITDA for today is -0.41.

The historical rank and industry rank for StageZero Life Sciences's EV-to-EBITDA or its related term are showing as below:

SZLSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.49   Med: -3.31   Max: -0.22
Current: -0.41

During the past 13 years, the highest EV-to-EBITDA of StageZero Life Sciences was -0.22. The lowest was -88.49. And the median was -3.31.

SZLSF's EV-to-EBITDA is ranked worse than
100% of 117 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.81 vs SZLSF: -0.41

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), StageZero Life Sciences's stock price is $0.04. StageZero Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.123. Therefore, StageZero Life Sciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


StageZero Life Sciences EV-to-EBITDA Historical Data

The historical data trend for StageZero Life Sciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences EV-to-EBITDA Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.15 -4.63 -5.14 -3.03 -0.60

StageZero Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -0.60 -0.76 -0.61 -0.52

Competitive Comparison of StageZero Life Sciences's EV-to-EBITDA

For the Diagnostics & Research subindustry, StageZero Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's EV-to-EBITDA falls into.



StageZero Life Sciences EV-to-EBITDA Calculation

StageZero Life Sciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4.927/-12.019
=-0.41

StageZero Life Sciences's current Enterprise Value is $4.93 Mil.
StageZero Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StageZero Life Sciences  (OTCPK:SZLSF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

StageZero Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.04/-0.123
=At Loss

StageZero Life Sciences's share price for today is $0.04.
StageZero Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.123.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


StageZero Life Sciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences (StageZero Life Sciences) Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.